SCHEMBL14933602

SCHEMBL14933602

Cc1c([C@@H](O)CN2CCC3(CC2)CCN(C[C@H](O)c2ccc4c(c2C)COC4=O)C3)ccc2c1COC2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 20/20 1.00
KCNH2 Q12809 9/20 0.79
ACHE P22303 1/20 0.79
SSTR1 P30872 1/20 0.79
SLC6A4 P31645 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16118006 0.95 KCNJ1 (0.90) KCNJ1KCNH2ACHESSTR1SLC6A4
SCHEMBL19264178 0.94 KCNJ1 (0.88) KCNJ1KCNH2ACHESSTR1SLC6A4
SCHEMBL17925038 0.93 KCNJ1 (0.86) KCNJ1KCNH2ACHESSTR1SLC6A4
SCHEMBL14933625 0.93 KCNJ1 (0.86) KCNJ1KCNH2ACHESSTR1SLC6A4
SCHEMBL19397993 0.93 KCNJ1 (0.86) KCNJ1KCNH2ACHESSTR1SLC6A4
SCHEMBL14933631 0.93 KCNJ1 (1.00) KCNJ1KCNH2ACHESSTR1SLC6A4
Hydrochloric Acid SCHEMBL19244724 0.92 KCNJ1 (0.85) KCNJ1KCNH2ACHESSTR1SLC6A4
SCHEMBL14933650 0.90 KCNJ1 (1.00) KCNJ1KCNH2ACHESSTR1SLC6A4
SCHEMBL19379385 0.90 KCNJ1 (0.81) KCNJ1KCNH2ACHESSTR1SLC6A4
SCHEMBL17697170 0.90 KCNJ1 (0.81) KCNJ1KCNH2ACHESSTR1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2773351-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2017-08-23 EP claimed
EP-2773351-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2017-08-23 EP disclosed
US-9493474-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
US-9493474-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
US-20140288042-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2014-09-25 US disclosed
US-20140288042-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2014-09-25 US disclosed
WO-2013066718-A2 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288042-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ2, KCNJ11, KCNK2 KCNJ1 5/4885KCNH2 6/4885ACHE 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.